Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?

Gynecologic Oncology

Volumn 75, Issue 3, 1999, Pages 464-467

  Higgins, Robert V ^a   Naumann, R Wendel ^a   Gardner, Joanne ^a   Hall, James B ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GROWTH FACTOR; PACLITAXEL; SEROTONIN 3 ANTAGONIST;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ELDERLY CARE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032763350     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5620     Document Type: Article

References (19)

1. McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
2. Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presti M, Torri W, Vassena L, Zanaboni F, Marsoni S. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian cancer. Cancer. 77:1996;733-742.
3. Taylor A E, Wiltshaw E, Gore M E, Fryatt I, Fisher C. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol. 12:1994;2066-2070.
4. Swenerton K D, Pater J L. Carboplatin in the treatment of carcinoma of the ovary: The National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee. Semin Oncol. 19:1992;114-119.
5. Hannigan E V, Green S, Alberts D S, O'Toole R, Surwit E. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology. 50:1993;2-9.
6. Ozols, R, F, Bundy, B, N, Fowler, J, Clarke-Pearson, D, Mannel, R, Hartenbach, E, M, Baergen, R, Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer. A Gynecologic Oncology Group Trial (GOG 158) Proc ASCO, Abstract 1373, 1999.
7. Oriel K A, Hartenbach E M, Remington P L. Trends in United States ovarian cancer mortality, 1979-1995. Obstet Gynecol. 93:1999;30-33.
8. Reis L G. Ovarian Cancer - Survival and treatment differences by age. Cancer. 71:1993;524-529.
9. U.S. Bureau of the Census Current Population Reports, Series P25-1130, Population Projections of the United States by Age, Sex, Race, and Hispanic Origin. pp, 1995, - 2050.
10. Miller, B, A, Ries, L, AG, Hankey, B, F, Kosary, C, L, Edwards, B, K, eds, Cancer Statistics Review: 1973-1989, Bethesda, MD, National Institutes of Health, National Cancer Institute;, 1992, Report No. 92-2789.
11. Averette H E, Janicek M F, Menck H R. The National Cancer Data Base Report on Ovarian Cancer. Cancer. 76:1995;1096-1103.
12. Lamy P P. Modifying drug dosage in elderly patients. Covington T R, Walker J I. Current Geriatric Therapy. 1984;35-72 Saunders, Philadelphia.
13. Newcomb P A, Carbone P P. Cancer treatment and age: Patient Perspectives. J Natl Cancer Inst. 85:1993;1580-1584.
14. Nerenz D R, Love R R, Leventhal H, Easterling D V. Psychosocial consequences of cancer chemotherapy for elderly patients. Health Serv Res. 20:1986;961-976.
15. Kimmick G, Fleming R, Muss H, Balducci L. Cancer chemotherapy in older adults: A tolerability perspective. Drugs Aging. 10:1997;34-49.
16. Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology. 6:1992;62-68.
17. Lipschitz D A. Age-related declines in hematopoietic reserve capacity. Semin Oncol. 22:1995;3-5.
18. Baker S D, Grochow L B. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 13:1997;169-184.
19. Begg C B, Carbone P P. Clinical trials and drug toxicity in the elderly: The experience of the Eastern Cooperative Oncology Group. Cancer. 52:1983;1986-1992.